USRE40812E1 - Nasal calcitonin formulation - Google Patents
Nasal calcitonin formulation Download PDFInfo
- Publication number
- USRE40812E1 USRE40812E1 US10/774,358 US77435804A USRE40812E US RE40812 E1 USRE40812 E1 US RE40812E1 US 77435804 A US77435804 A US 77435804A US RE40812 E USRE40812 E US RE40812E
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- calcitonin
- liquid pharmaceutical
- composition
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to an intranasal pharmaceutical compositions comprising calcitonin as an active ingredient and specific concentrations of citric acid or a salt thereof as a stabilizer and absorption enhancer.
- Calcitonins are a class of polypeptide hormones that are used in the treatment of a variety of conditions including osteoporosis, Pagel's disease and malignant hypercalcemia. They are composed of amino acids and have been extracted from a number of sources including salmon, porcine, eel and human. Calcitonins with amino acid sequences identical to the natural forms have been produced by chemical synthesis as well as by recombinant technology.
- calcitonins were originally administered by subcutaneous or intramuscular injection. Other routes of administration were technically difficult because calcitonins were poorly absorbed through tissue and were readily degraded by bodily fluids. Despite these obstacles, a formulation (U.S. Pat. No. 5,759, 565) was developed that could be administered via the nasal route.
- the nasal formulation was designed to be stored in a multi-dose container that was stable for an extended period of time and resisted bacterial contamination.
- the preservative in the formulation, benzalkonium chloride was found to enhance the absorption of salmon calcitonin. However, benzalkonium chloride was reported (P. Graf et al., Clin. Exp.
- the present invention provides a liquid pharmaceutical composition
- a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.
- the present invention also provides a liquid pharmaceutical composition
- a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% TWEEN® 80.
- the present invention further provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benyzl alcohol, and about 0.1% TWEEN® 80.
- the present invention also provides a method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering via the nasal route to said subject a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 to about 50 mM.
- the present invention further provides a method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition.
- the present invention also provides a method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition prior to said administration.
- compositions comprising a calcitonin as active ingredient which meet the high standards of stability and bioavailability required for nasal application and which are, for example, eminently suitable for use in multiple dose nasal spray applicators, i.e., applicators capable of delivering a series of individual dosages over, e.g., period of several days or weeks, by the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM as a buffering agent.
- citric acid or a salt thereof at increasing concentrations confers beneficial advantages in relation to the nasal absorption characteristics of calcitonin containing compositions and hence enhance calcitonin bioavailability levels consequential to nasal application.
- use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM increase the stability of calcitonin containing compositions while at the same time higher concentrations of citric acid or salt thereof did not have the same stabilizing effect.
- the calcitonins for use in the invention may be in free form or in pharmaceutically acceptable salt or complex form, e.g. in pharmaceutically acceptable acid addition salt form.
- Such salts and complexes are known and possess an equivalent degree of activity and tolerability to the free forms.
- Suitable acid addition salt forms for use in accordance with the invention include for example the hydrochlorides and acetates.
- compositions may be applied in accordance with the invention to the nasal mucosa, e.g. either in drop or in spray form. As hereinafter described however, they are most preferably applied in spray form, i.e., in the form of finely divided droplets.
- compositions of the invention may of course also include additional ingredients, in particular components belonging to the class of conventional pharmaceutically applicable surfactants.
- additional ingredients in particular components belonging to the class of conventional pharmaceutically applicable surfactants.
- surface active agents generally in relation to the nasal application of calcitonins, in particular salmon calcitonin, may increase absorption via the nasal mucosa and hence improve obtained bioavailability rates.
- the liquid pharmaceutical calcitonin composition of the present invention contains a pharmaceutically acceptable, a liquid diluent or carrier suitable for application to the nasal mucosa, most preferably aqueous saline.
- compositions of the invention are formulated so as to permit administration via the nasal route.
- they may also contain, e.g. minimum amounts of any additional ingredients or excipients desired, for example, additional preservatives or, e.g. ciliary stimulants such as caffeine.
- compositions of the invention have a pH of from about 3 to 5, more preferably from about 3.5 to about 3.9 and most preferably 3.7. Adjustment of the pH is achieved by addition of an appropriate acid, such as hydrochloric acid.
- compositions of the invention should also possess an appropriate isotonicity and viscosity. Preferably they have an osmotic pressure of from about 260 to about 380 mOsm/liter. Desired viscosity for the nasal spray is preferably less than 0.98 cP. In one embodiment, the osmotic pressure is from 250 to 350 mOsm/liter.
- compositions in accordance with the present invention may also comprise a conventional surfactant, preferably a non-ionic surfactant.
- the amount present in the compositions of the invention will vary depending on the particular surfactant chosen, the particular mode of administration (e.g. drop or spray) and the effect desired. In general, however, the amount present will be of the order of from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5 mg/ml to 5 mg/ml and most preferably about 1 mg/ml.
- the amount of calcitonin to be administered in accordance with the method of the invention and hence the amount of active ingredient in the composition of the invention will, of course, depend on the particular calcitonin chosen, the condition to be treated, the desired frequency of administration and the effect desired.
- bioavailability for calcitonins in particular salmon calcitonin, as determined in terms of blood-plasma concentration following nasal administration in accordance with the teachings of the present invention has been found to be surprisingly high.
- treatment will therefore suitably comprise administration of dosages of from about 50 to about 400 MRC units, more preferably from about 100 to about 200 MRC units at a frequency of from about once daily to about three times weekly.
- dosages as aforesaid will be administered in a single application, i.e., treatment will comprise administration of single nasal dosages comprising about 50 to about 400 MRC units, preferably about 100 to about 200 MRC units, calcitonin.
- dosages may be split over a series of 2 to 4 applications taken at intervals during the day, the dosage at each application then comprising about 10 to about 200, preferably about 25 to about 100 MRC units.
- composition quantity administered at each nasal application suitably comprises from about 0.05 to about 0.15 ml, typically about 0.1 ml.
- Compositions for use in accordance with the invention accordingly suitably comprise from about 150 to about 8,000, preferably from about 500 to about 4,000, more preferably from about 500 to about 3,000, yet again more preferably from about 1,000 to about 2,500, and most preferably about 2,200 MRC units of calcitonin per ml.
- compositions of the invention will preferably be put up in a container provided with means enabling application of the contained composition to the nasal mucosa, e.g. put up in a nasal applicator device.
- Suitable applicators are known in the art and include those adapted for administration of liquid compositions to the nasal mucosa in drop or spray form. Since dosaging with calcitonins should be as accurately controlled as possible use of spray applicators for which the administered quantity is susceptible to precise relation will generally be preferred.
- Suitable administrators include, e.g. atomizing devices, e.g. pump-atomizers and aerosol dispensers.
- the applicator will contain a composition in accordance with the invention together with a propellant medium suitable for use in a nasal applicator.
- the atomizing device will be provided with an appropriate spray adaptor allowing delivery of the contained composition to the nasal mucosa. Such devices are well known in the art.
- the container e.g. nasal applicator
- the container may contain sufficient composition for a single nasal dosaging or for the supply of several sequential dosages, e.g. over a period of days or weeks. Quantities of individual dosages supplied will preferably be as hereinbefore defined.
- the stability of the compositions of the invention may be determined in conventional manner. As indicated hereinbelow, the calcitonin content of the compositions of the invention will degrade less than 50 % in 15 days at 50° C. as indicated by standard analytical tests.
- sCT salmon calcitonin
- blood samples are collected prior to dosing and at 5, 15, 30, 60 and 120 minutes after dosing.
- blood samples are collected prior to dosing and at 30, 60, 90, 120 and 150 minutes after the administration of the first dose. Blood samples are always collected immediately before the administration of any additional costs doses.
- Each sample (0.5 ml) of blood is collected into a heparinized 1 ml syringes and then transferred to chilled 1.5 ml polypropylene tubes containing 10 ⁇ l of herparin (500 U per ml).
- the tubes are centrifuged at approximately 3000 rpm for 20 minutes at 2-8° C. and the plasma supernatant is transferred to microcentrifuge tubes that were stored at ⁇ 20° C.
- the concentration of sCT in plasma is determined by a competitive radioimmunosaasy. Aliquots of the plasma samples and standards are incubated for 4 hours at room temperature with rabbit anti-sCT antibody. Subsequently, 125 I-sCT is added and incubated overnight at 2-8° C.
- Antibody-bound 125 I-sCT is isolated the next day by precipitating it with normal rabbit antiserum and goat anti-rabbit antibody. Radioactivity associated with the resulting pellets is measured with a gamma counter. The concentration of sCT in plasma is inversely proportional to the amount of radioactivity that was precipitated.
- Cmax are determined by inspection and the values for bioavailability (relative to an intravenous injection) are calculated from the areas under the curve that were obtained from plots of plasma sCT concentration as a function of time.
- sCT 200 ⁇ g/ml
- TWEEN® 80 0.85% sodium chloride
- TWEEN® 80 0.1%
- Table 2 indicate that the bioavailability and peak concentration of rsCT are not significantly affected by the addition of the different preservatives.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
TABLE 1 |
EFFECT OF THE CONCENTRATION OF CITRIC ACID |
ON THE BIOAVAILABILITY AND PLASMA |
CONCENTRATION OF SALMON CALCITONIN |
ADMINISTERED INTRANASALLY TO RATS |
Citric acid | Bioavailability | Maximum plasma sCT |
(pH 3.7) | (percent ± sdev) | (ng/ml ± sdev) |
0 | 0.89 ± 0.19 | 1.10 ± 0.52 |
10 | 3.14 ± 1.77 | 3.66 ± 1.67 |
25 | 5.01 ± 2.34 | 5.11 ± 2.09 |
50 | 6.15 ± 1.31 | 6.05 ± 1.30 |
100 | 13.36 ± 3.38 | 12.98 ± 3.96 |
TABLE 2 |
EFFECT OF PRESERVATIVES ON THE |
AVAILABILITY AND PLASMA CONCENTRATION |
OF SCT ADMINISTERED INTRANASALLY TO RATS |
Bioavailability | Maximum plasma sCT | |
Preservatives | (percent ± sdev) | (ng/ml ± sdev) |
None | 1.14 ± 0.87 | 1.24 ± 0.79 |
0.2% phenyethyl alcohol- | 0.89 ± 0.19 | 1.10 ± 0.52 |
0.5% benzyl alcohol | ||
0.27 methyl parabens- | 1.08 ± 0.86 | 1.47 ± 1.46 |
0.04% propyl parabens | ||
TABLE 3 |
EFFECT OF THE CONCENTRATION OF |
CITRIC ACID ON THE STABILITY OF |
sCT STORED FOR VARYING PERIODS AT 50° C. |
Percent sCT Recovered |
Days at | Citric Acid (pH 3.7) |
50° C. | 0 Mm | 10 mM | 20 mM | 50 mM | 100 mM |
9 | 100 | 100 | 100 | 100 | 100 |
3 | 83 | 94 | 91 | 90 | 87 |
6 | 53 | 90 | 87 | 83 | 77 |
9 | 24 | 82 | 78 | 73 | 66 |
15 | 22 | 74 | 68 | 61 | 20 |
Claims (29)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/774,358 USRE40812E1 (en) | 2000-02-04 | 2004-02-05 | Nasal calcitonin formulation |
US12/459,385 USRE43580E1 (en) | 2000-02-04 | 2009-06-29 | Nasal calcitonin formulations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18024100P | 2000-02-04 | 2000-02-04 | |
US09/776,537 US6440392B1 (en) | 2000-02-04 | 2001-02-02 | Nasal calcitonin formulations |
US10/774,358 USRE40812E1 (en) | 2000-02-04 | 2004-02-05 | Nasal calcitonin formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/776,537 Reissue US6440392B1 (en) | 2000-02-04 | 2001-02-02 | Nasal calcitonin formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/776,537 Continuation US6440392B1 (en) | 2000-02-04 | 2001-02-02 | Nasal calcitonin formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE40812E1 true USRE40812E1 (en) | 2009-06-30 |
Family
ID=22659737
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/776,537 Ceased US6440392B1 (en) | 2000-02-04 | 2001-02-02 | Nasal calcitonin formulations |
US10/774,358 Expired - Lifetime USRE40812E1 (en) | 2000-02-04 | 2004-02-05 | Nasal calcitonin formulation |
US12/459,385 Expired - Lifetime USRE43580E1 (en) | 2000-02-04 | 2009-06-29 | Nasal calcitonin formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/776,537 Ceased US6440392B1 (en) | 2000-02-04 | 2001-02-02 | Nasal calcitonin formulations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/459,385 Expired - Lifetime USRE43580E1 (en) | 2000-02-04 | 2009-06-29 | Nasal calcitonin formulations |
Country Status (6)
Country | Link |
---|---|
US (3) | US6440392B1 (en) |
EP (1) | EP1251867A4 (en) |
CN (1) | CN1183965C (en) |
AU (1) | AU783952B2 (en) |
CA (1) | CA2399505C (en) |
WO (1) | WO2001056594A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090317462A1 (en) * | 2007-05-29 | 2009-12-24 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US20100256060A1 (en) * | 2009-04-02 | 2010-10-07 | Unigene Laboratories Inc. | Peptide pharmaceuticals for nasal delivery |
USRE43580E1 (en) * | 2000-02-04 | 2012-08-14 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
US9457086B2 (en) | 2013-03-05 | 2016-10-04 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
US9833411B2 (en) | 2015-01-12 | 2017-12-05 | Enteris Biopharma, Inc. | Solid oral dosage forms |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
WO2005000222A2 (en) | 2003-05-30 | 2005-01-06 | Amylin Pharmaceuticals, Inc. | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
CN1546169A (en) * | 2003-12-16 | 2004-11-17 | 上海医药工业研究院 | Transnasal inhalant dry powder of calcitonin and its preparation |
ITMI20040235A1 (en) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
CN101549149B (en) * | 2008-09-17 | 2011-12-28 | 北京双鹭药业股份有限公司 | New nasal spray formulation of calcitonin aqueous solution |
CN108969754B (en) * | 2018-09-04 | 2019-06-21 | 深圳大佛药业股份有限公司 | A kind of Salmon Calcitonin Nasal Spray and preparation method thereof |
Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151276A (en) | 1975-05-12 | 1979-04-24 | Armour Pharmaceutical Company | Method of suppressing gastric acid secretion by the oral administration of calcitonin |
GB2092002A (en) * | 1981-01-14 | 1982-08-11 | Toyo Jozo Kk | Suppositories, injectable solutions |
EP0115627A1 (en) | 1982-12-29 | 1984-08-15 | Armour Pharmaceutical Company | Enhancement of intranasal absorption of calcitonin by formulation with surfactants |
US4690952A (en) | 1984-11-26 | 1987-09-01 | Yamanouchi Pharmaceutical Co., Inc. | Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance |
US4845080A (en) | 1983-06-27 | 1989-07-04 | Ciba-Geigy Corporation | Human calcitonin peptide with salmon calcitonin-like characteristics |
EP0327756A2 (en) | 1987-11-13 | 1989-08-16 | Smithkline Beecham Farmaceutici S.p.A. | Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer |
US4900730A (en) | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
EP0358234A2 (en) | 1988-09-08 | 1990-03-14 | Rhone-Poulenc Rorer International (Holdings) Inc. | Intranasal calcitonin formulations |
EP0418697A1 (en) | 1989-09-15 | 1991-03-27 | ESSETI s.a.s. LABORATORIO CHIMICO FARMACO BIOLOGICO DI A. IEVOLI & C. | Pharmaceutical compositions containing calcitonin |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
EP0489217A1 (en) | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
US5124315A (en) | 1989-11-16 | 1992-06-23 | Phideatech S.R.L. | Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient |
JPH0578258A (en) | 1991-09-20 | 1993-03-30 | Suntory Ltd | Stable calcitonin medicinal composition and its production |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5279836A (en) | 1991-02-19 | 1994-01-18 | Mediator S.R.L. | Topical use of calcitonin for the preparation of medications in senile idiopathic cataract and a pharmaeutical composition thereof |
US5281580A (en) | 1990-08-16 | 1994-01-25 | Toyo Jozo Company, Ltd. | Calcitonin-containing emulsion for nasal administration |
US5310727A (en) | 1986-06-20 | 1994-05-10 | Scalvo S.P.A. | Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient |
US5496801A (en) | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
US5514365A (en) | 1988-10-11 | 1996-05-07 | Schiapparelli Salute S.P.A. | Pharmaceutical compositions comprising calcitonin for intranasal administration |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5536508A (en) | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
EP0726075A1 (en) | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
US5571788A (en) | 1991-12-09 | 1996-11-05 | Ciba-Geigy Corporation | Stable calcitonin pharmaceutical compositions |
US5593962A (en) | 1991-04-23 | 1997-01-14 | Ciba-Geigy Corporation | Fibrillated calcitonin pharmaceutical compositions |
US5637309A (en) | 1993-09-20 | 1997-06-10 | Shiseido Company, Ltd. | Physiologically active substance-prolonged releasing-type pharmaceutical preparation |
US5654000A (en) | 1992-07-28 | 1997-08-05 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
US5665700A (en) | 1990-03-29 | 1997-09-09 | Skua Investments Limited | Pharmaceutical formulations |
US5693608A (en) | 1990-05-10 | 1997-12-02 | Bechgaard International Research And Development A/S | Method of administering a biologically active substance |
US5714477A (en) | 1993-06-18 | 1998-02-03 | Pharmacia & Upjohn Aktiebolag | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters |
US5719122A (en) | 1992-10-20 | 1998-02-17 | Smithkline Beecham Farmaceutici S.P.A. | Pharmaceutical compositions containing a calcitonin |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5726154A (en) | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
US5733569A (en) * | 1982-10-05 | 1998-03-31 | Novartis Corporation | Galenic compositions comprising calcitonin and their use |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5759566A (en) | 1992-07-28 | 1998-06-02 | Poli Industria Chimica Spa | Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents |
US5776886A (en) | 1993-06-07 | 1998-07-07 | Teikoku Seiyaku Kabushiki Kaisha | Intravaginal preparation containing physiologically active peptide |
US5858391A (en) | 1994-06-20 | 1999-01-12 | Kv Pharmaceutical Company | Long acting GI and esophageal protectant |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5968899A (en) | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
US6017538A (en) | 1992-10-19 | 2000-01-25 | Institut Pasteur | Plasmodium falciparum antigens inducing protective antibodies |
US6149893A (en) | 1999-03-01 | 2000-11-21 | Alfa Wassermann S.P.A. | Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6348207B1 (en) | 1992-06-15 | 2002-02-19 | Emisiphere Technologies, Inc. | Orally deliverable supramolecular complex |
US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
US6440392B1 (en) | 2000-02-04 | 2002-08-27 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
US6447785B1 (en) | 2000-02-15 | 2002-09-10 | Allergan Sales, Inc. | Method for treating hypercalcemia |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5885813A (en) | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | Drug preparation having high absorbability |
US5169849A (en) | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
-
2001
- 2001-01-31 AU AU36604/01A patent/AU783952B2/en not_active Ceased
- 2001-01-31 EP EP01908769A patent/EP1251867A4/en not_active Withdrawn
- 2001-01-31 CA CA2399505A patent/CA2399505C/en not_active Expired - Fee Related
- 2001-01-31 WO PCT/US2001/003212 patent/WO2001056594A1/en active IP Right Grant
- 2001-01-31 CN CNB01807605XA patent/CN1183965C/en not_active Expired - Fee Related
- 2001-02-02 US US09/776,537 patent/US6440392B1/en not_active Ceased
-
2004
- 2004-02-05 US US10/774,358 patent/USRE40812E1/en not_active Expired - Lifetime
-
2009
- 2009-06-29 US US12/459,385 patent/USRE43580E1/en not_active Expired - Lifetime
Patent Citations (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151276A (en) | 1975-05-12 | 1979-04-24 | Armour Pharmaceutical Company | Method of suppressing gastric acid secretion by the oral administration of calcitonin |
GB2092002A (en) * | 1981-01-14 | 1982-08-11 | Toyo Jozo Kk | Suppositories, injectable solutions |
US4900730A (en) | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
US5759565A (en) | 1982-10-05 | 1998-06-02 | Novartis Corporation | Galenic compositions comprising calcitonin and their use |
US5733569A (en) * | 1982-10-05 | 1998-03-31 | Novartis Corporation | Galenic compositions comprising calcitonin and their use |
EP0115627A1 (en) | 1982-12-29 | 1984-08-15 | Armour Pharmaceutical Company | Enhancement of intranasal absorption of calcitonin by formulation with surfactants |
US4845080A (en) | 1983-06-27 | 1989-07-04 | Ciba-Geigy Corporation | Human calcitonin peptide with salmon calcitonin-like characteristics |
US4690952A (en) | 1984-11-26 | 1987-09-01 | Yamanouchi Pharmaceutical Co., Inc. | Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance |
US4788221A (en) | 1984-11-26 | 1988-11-29 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions comprising calcitonin and an absorption-promoting substance |
EP0371010A1 (en) | 1984-11-26 | 1990-05-30 | Yamanouchi Pharmaceutical Co. Ltd. | Absorbable calcitonin medicament |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5310727A (en) | 1986-06-20 | 1994-05-10 | Scalvo S.P.A. | Pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
US5183802A (en) | 1987-11-13 | 1993-02-02 | Isf Societa Per Azioni | Pharmaceutical compositions for intranasal administration of calcitonin |
EP0327756A2 (en) | 1987-11-13 | 1989-08-16 | Smithkline Beecham Farmaceutici S.p.A. | Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer |
EP0358234A2 (en) | 1988-09-08 | 1990-03-14 | Rhone-Poulenc Rorer International (Holdings) Inc. | Intranasal calcitonin formulations |
US5026825A (en) | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
US5514365A (en) | 1988-10-11 | 1996-05-07 | Schiapparelli Salute S.P.A. | Pharmaceutical compositions comprising calcitonin for intranasal administration |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
EP0418697A1 (en) | 1989-09-15 | 1991-03-27 | ESSETI s.a.s. LABORATORIO CHIMICO FARMACO BIOLOGICO DI A. IEVOLI & C. | Pharmaceutical compositions containing calcitonin |
US5124315A (en) | 1989-11-16 | 1992-06-23 | Phideatech S.R.L. | Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5665700A (en) | 1990-03-29 | 1997-09-09 | Skua Investments Limited | Pharmaceutical formulations |
US5693608A (en) | 1990-05-10 | 1997-12-02 | Bechgaard International Research And Development A/S | Method of administering a biologically active substance |
US5281580A (en) | 1990-08-16 | 1994-01-25 | Toyo Jozo Company, Ltd. | Calcitonin-containing emulsion for nasal administration |
US5700486A (en) | 1990-11-22 | 1997-12-23 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
US5536508A (en) | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
EP0489217A1 (en) | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
US5279836A (en) | 1991-02-19 | 1994-01-18 | Mediator S.R.L. | Topical use of calcitonin for the preparation of medications in senile idiopathic cataract and a pharmaeutical composition thereof |
US5593962A (en) | 1991-04-23 | 1997-01-14 | Ciba-Geigy Corporation | Fibrillated calcitonin pharmaceutical compositions |
JPH0578258A (en) | 1991-09-20 | 1993-03-30 | Suntory Ltd | Stable calcitonin medicinal composition and its production |
US5571788A (en) | 1991-12-09 | 1996-11-05 | Ciba-Geigy Corporation | Stable calcitonin pharmaceutical compositions |
US6348207B1 (en) | 1992-06-15 | 2002-02-19 | Emisiphere Technologies, Inc. | Orally deliverable supramolecular complex |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US5654000A (en) | 1992-07-28 | 1997-08-05 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
US5759566A (en) | 1992-07-28 | 1998-06-02 | Poli Industria Chimica Spa | Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents |
US6017538A (en) | 1992-10-19 | 2000-01-25 | Institut Pasteur | Plasmodium falciparum antigens inducing protective antibodies |
US5719122A (en) | 1992-10-20 | 1998-02-17 | Smithkline Beecham Farmaceutici S.P.A. | Pharmaceutical compositions containing a calcitonin |
US6008189A (en) | 1993-06-07 | 1999-12-28 | Teikoku Seiyaku Kabushiki Kaisha | Intravaginal preparation containing physiologically active peptide |
US5776886A (en) | 1993-06-07 | 1998-07-07 | Teikoku Seiyaku Kabushiki Kaisha | Intravaginal preparation containing physiologically active peptide |
US5714477A (en) | 1993-06-18 | 1998-02-03 | Pharmacia & Upjohn Aktiebolag | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters |
US5637309A (en) | 1993-09-20 | 1997-06-10 | Shiseido Company, Ltd. | Physiologically active substance-prolonged releasing-type pharmaceutical preparation |
US5496801A (en) | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
US5968899A (en) | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
US5858391A (en) | 1994-06-20 | 1999-01-12 | Kv Pharmaceutical Company | Long acting GI and esophageal protectant |
US6087338A (en) | 1995-02-08 | 2000-07-11 | Therapicon S.R.L. | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
EP0809512A1 (en) | 1995-02-08 | 1997-12-03 | Therapicon Srl | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin |
US6107277A (en) | 1995-02-08 | 2000-08-22 | Therapicon S.R.L. | Calcitonin salmon analogues |
EP0726075A1 (en) | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
US6086918A (en) | 1996-03-15 | 2000-07-11 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical products |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5726154A (en) | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6149893A (en) | 1999-03-01 | 2000-11-21 | Alfa Wassermann S.P.A. | Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration |
US6440392B1 (en) | 2000-02-04 | 2002-08-27 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
US6447785B1 (en) | 2000-02-15 | 2002-09-10 | Allergan Sales, Inc. | Method for treating hypercalcemia |
Non-Patent Citations (93)
Title |
---|
A.E. Pontiroli, et al., Intranasal calcitonin and plasma calcium concentrations in normal subjects, British Medical Journal, Clinical Research ed., 290:1390-1391. (1985). |
Abe K., et al., Chem. Pharm. Bull (Tokyo) Dec. 1995; 43 (12): 2232-7, "Enhanced Nasal Delivery of Luteinizing Hormone Releasing Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-beta-cyclodextrin", abstract. |
Agerholm C., et al., J. Pharm. Sci. Dec. 1994; 83 (12) : 1706-11, "Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in Rabbits", abstract. |
Akers and DeFelippis, Pharmaceutical Formulation Development of Peptides and Proteins, (published 2000), Sven Frokjaer and Lars Hovgaard, Editors Pharmaceutical Formulation Development of Peptides and Proteins, pp. 145-177, CRC Press 2000. |
Akwete Lex Adjei and Pramod K. Gupta, Editors, Inhalation Delivery of Therapeutic Peptides and Proteins, 1997:493-514, Marcel Dekker, Inc. |
Amended Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., Civil Action No. 06-CV-5571-RPP-THK EFC Case (S.D.N.Y.), May 8, 2007. |
Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories Inc., et al. v. Apotex Inc., et al., Civil Action No. 06-CV-5571-RPP-THK, EFC Case (S.D.N.Y.) Sep. 20, 2006. |
Apotex Notice Letter-Jun. 1, 2006. |
Armyn P. Sayani, et al. "Systemic Delivery of Peptides and Proteins Across Absorptive Mucoase", Critical Reviews in Therapeutic Drug Carrier Systems, 13 (1&2):85-184 at pp. 106,127,128,144,158,160 (1996). |
Bell, L.N., "Peptide stability in solids and solutions", Biotechnology Progress 13:342-346. (1997). |
Berg et al., Laryngoscope 104:1153-1158; 1994 "The Effect of Decongestive Nosedrops on Human Respiratory Mucosa In Vitro". |
Biotechnology Newswatch, vol. 9, No. 12; p. 1, "Two-nasally delivered CalBio hormones pass initial clinicals", Jun. 19, 1989. |
Caspar W.R., et al. , Drug & Cosmetic Industry, vol. 156; No. 1; p. 46, "New Ways of Enhancing the Delivery of Skin Care Ingredients", Jan. 1995. |
Complaint by Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., 06-cv-5571-RPP-THK (EFC Case)-U.S. District Court for the Southern District of New York. |
Critchley H., et al., J. Pharm Pharmacol Aug. 1994; 46 (8) : 651-6, "Nasal Absorption of Desmpressin in Rats and Sheep. Effect of A Bioadhesive Microsphere Delivery System", abstract. |
D. Harris, et al., "Bioadhesive polymers in peptide drug delivery", Biomaterials, 11:652-658. (1990). |
D. Voet and J.G. Voet, Biochemistry, 2nd Edition, John Wiley & Sons, New York, pp. 538-541 (1995). |
Database WPI, Section Ch, Week 199317, Derwent Publications Ltd., London, GB; Class B04, AN 1993-140304, XP002300282 & JP 05 078258 A (Suntory) Mar. 30, 1993. |
Declaration of Ashim K. Mitra, Ph.D. Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. |
Declaration of Michael Sofocleous dated Oct. 13, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. |
Declaration of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. |
Declaration of Professor Robert S. Langer Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. |
Donovan M.D., et al., Pharm. Res. Aug. 1990; 7 (8) : 808-15, "The Molecular Weight Dependence of Nasal Absorption: the Effect of Absorption Enhancers", abstract. |
Dua et al., International Journal of Pharmaceutics 147, 1997, pp. 233-242 "The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits." |
European Search Report dated Oct. 10, 2004. |
Expert Report of Dr. Robert P. Raymond, Esq., dated Dec. 2, 2008, pp. 1-23. |
Expert Report of Henry Kwan, Ph.D. Regarding Validity of U.S. Pat. No. 6,440,392, dated Dec. 2, 2008, pp. 1-182. |
Feb. 20, 2008 Defendants' Notice of Motion in Support of Defendants' Motion For Reconsideration of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
Feb. 20, 2008 Memorandum of Law in Support of Defendants' Motion for Reconsideration of the of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
Feb. 28, 2008 Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
Feb. 4, 2008 Opinion and Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
H. Hallen et al., Clin. Exp. Allergy, vol. 25:401-405; 1995 "Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers". |
Hayashi, et al., "Physiological mechanism for enhancement of paracellular drug transport", Journal of Controlled Release, 62: 141-148. (1999). |
Hosoya K., et al., Biol Pharm Bull Feb. 1994; 17 (2) : 316-22, "Evaluation of Enhancers to Increase Nasal Absorption Using Ussing Chamber Technique", abstract. |
Jacobs M.A., et al., Diabetes Nov. 1993; 41 (11) : 1649-55, "The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers", abstract. |
Jul. 14, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). |
Jul. 15, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). |
Jul. 16, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). |
Kagatani S., et al., Pharm. Res. 1996 13/5 (739-743), "Enhancement of Nasal Salmon Calcitonin Absorption by Lauroyclarnitine Chloride in Rats", abstract. |
Kobayashi, S., et al., "Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats", Pharmaceutical Research, 13:80-83. (1996). |
Kurosaki Y., et al., J. Pharmacobiodyn Dec. 1988; 11 (12) : 824-32, "Application of Propranolol to the Keratinized Oral Mucosa: Avoidance of First-Pass Elimination and the Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form", abstract. |
Lee, K.C. et al., "Degradation of synthetic salmon calcitonin in aqueous solutions", Pharm. Res. 9:1521-1523. (1992). |
Li, Y., et al., "Effect of a conjugated bile salt on the pulmonary absorption of insulin in rats", Eur. J. Pharm. Biopharm, 39:216-21. (1993). |
M. Gibson, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commerical Dosage Form, p. 479 and Chapter 13, Aqueous Nasal Dosage Forms, Ed., Taylor & Francis. (2001). |
M. Weiner and I. Leonard Bernstein, 1989, Adverse Reactions to Drug Formulation Agents, A Handbook of Excipients, Marcel Dekker, Inc. 1989, pp. 361-363 and 390-391. |
M.J. Cho., et al., "Citric acid as an adjuvant for transepithelial transport" International Journal of Pharmaceutics, 52:79-81. (1989). |
Martin E., et al., Pharm Res May 1997; 14(5) : 631-7, "Confocal laser scanning microscopic visualization of the transport of Dextrans after Nasal Administration to Rats: Effects of Absorption Enhancers", abstract. |
Marttin E., Pharm. Res., May 1997, 14 (5): 631-7, "Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers", abstract. |
Morimoto K., et al., J. Pharma. Pharmacol. 1985 37/2 (134-136) "Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel", abstract. |
Morimoto K., et al., Pharm Res Sep. 1991; 8 (9) : 1175-9, "Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasoppressin and an Analogue", abstract. |
N.R. Anderson, et al., "Quantitative evaluation of pharmaceutical effervescent systems II: Stability monitoring by reactivity and porosity measurements", Journal of Pharmaceutical Sciences, 71:7-13. (1982). |
Nov. 6, 2007 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
Observations on European Patent Application No. EP 1251867 (third party observations) dated Jan. 17, 2003. |
Office Action from the European Patent Office concerning European Application Serial No. 01 908 769.1-1219 dated Feb. 2, 2007. |
Okamoto H., et al., J. Pharm. Pharmacol Jul. 1987; 39 (7) : 531-4, "Enhanced penetration of mitromycin C through hairless mouse and rats skin by enhancers with terpene moieties", abstract. |
Opinion and Order dated Aug. 28, 2008, in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06, CV 5571 (RPP). |
P. Graf et al., Clin., Exp. Allergy, vol. 25:395-400; 1995 "Benzalkoium chloride in a decongestant nasal spray aggravates Rhinitis medicamentosa in healthy volunteers". |
P. Nykänen, et al., "Organic acids as excipients in matrix granules for colon-specific drug delivery", Int. J. Pharm. 184:251-261. (1999). |
P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992 "The effects of calcitonin nsala preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test". |
Patent family search for EP 0358234 (equiv. USP 5,026,825),1/34/1 Dialog(R) File 351:Derwent abstract, (008189979, "Intranasal calcitonin formulations-contg. Delta-amino-laevulinic acid for enhanced bioavailability" (priority application 1988). |
Patent family search for GB 2212062 (equiv. EP 0327756), 2/34/1 Dialog(R) File 351: Derwent abstract, 007943804, "Pharmaceutical Calcitonin-contg. for nasal glycyrrihizinate to enhance mucosal membrane absorption, esp. for nasal administration" (priority application 1987). |
Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & Wilkins, pp. 77-81 (1999). |
Physicians' Desk Reference 52nd Edition at 1880-1881 (1998). |
Physicians' Desk Reference-PDR 53 Edition 1999, pp. 2057-2059. |
Pillion D.J., et al., J. Pharm. Sci. Nov. 1995; 84 (11) : 1276-9, "DS-1, A Modified Quillaja Saponin, Enhances Ocula and Nasal Absorption of Insulin", abstract. |
Plaintiffs' Memorandum of Law in Opposition to Defendants' Motion for Reconsideration of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). |
Pontiroli A.E., et al., Eur J Clin Pharmacol 1989; 37 (4) : 427-30, "Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: A Comparison of Powders and Spray Solutions and of Different Enhancing Agents", abstract. |
R.C. Henrikson, et al., Histology, Lippincott Williams and Wilkins pp. 311-321 at 314 (1997). |
Ratafia, Manny, et al. M&M Medical Marketing & Media, vol. 24; No. 11, p. 10; "Drug Delivery: the Key to Biotechnology Markets", Oct. 1, 1989. |
Rebuttal Declaration and Expert Report of Ashim K. Mitra, Ph.D. |
Rebuttal Declaration and Expert Report of Michael Sofocleous. |
Rebuttal Declaration and Expert Report of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Pat. No. 6,440,392. |
Rebuttal Declaration and Expert Report of Professor Robert S. Langer Regarding Invalidity of U.S. Pat. No. 6,440,392. |
Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia (USA) Jan. 2000, Chapter 47, pp. 922-923. |
Repertorio Farmaceutico Italiano, REFI 4a Edizione (REFI 4th Edition), 1990, p. A 212, (Calcitonina Spray Nasale Arnmour, and p. A223 "Carbicalcin Spray", Farmindustria, Associazione dell'Idustria Farmaceutica (National Association of the Pharmaceutical Industry)-CEDOF Editor, 1990. |
Reubsaet et al., "Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P{6-11} in aqueous solutions", Analytical Biochemistry 227:334-341. (1995). |
Romeijn S.G., et al., Int. J. Pharm.,1996,135/1-2 (137-145), "The Effect of Nasal Drug Formulations on Ciliary Beating in vitro", abstract. |
Santus G., et al., Farmaco Dec. 1993; 48 (12) : 1709-33, "Nasal Formulations of Ketorolac Tromethamine: Technological Evaluation-Bioavailability and Tolerability in Rabbits", abstract. |
Sarkar M.A., Pharm Res Jan. 1992; 9 (1) : 1-9, "Drug Metabolism in the Nasal Mucosa", abstract. |
Schipper N.G., et al., Pharm Res Nov. 1996; 13 (11) : 1686-92, "Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells", abstract. |
Schipper N.G.M., et al., Calcif. Tissue Int.,1995, 56/4 (280-282) "Methylated (beta)-cyclodextrins are Able to Improve the Nasal Absorption of Salmon Calcitonin", abstract. |
Second Declaration of Inventor William Stern Under 37 CFR § 1.132 dated Sep. 7, 2007. |
Shao Z., et al., Pharm Res Sep. 1992: 9 (9) : 1157-63, "Cyclodextrins as Nasal Absorption Promoters of Insulin : Mechanistic Evaluations", abstract. |
Stephen G. Farmer and Douglas W.P. Hay, Editors, The Airway Epithelium: Physiology, Pathophysiology and Pharmacology 1991: 3-39, Marcel Dekker, Inc. |
Sugibayashi K., et al., J. Pharm. Pharmacol Aug. 1985; 37 (8) : 578-80, "Effect of the Absorption Enhancer, Azone, on the Transport of 5-Fluorouracil Across Hairless Rat Skin", abstract. |
Tengamnuay P., et al., Pharm Res Apr. 1990; 7 (4) : 370-5, "Bile Salt-Fatty Acid Mixed Micelles as Nasal Absorption Promoters of Peptides. II. In vivo Nasal Absorption of Insulin in Rats and Effects of Mixed Micelles on the Morphological Integrity of the Nasal Mucosa", abstract. |
The Merck Index, 13th Edition, 2001, p. 3576. |
Third Declaration of inventor William Stern under 37 C.F.R. § 1.132, with Exhibits. |
Tyler-Cross et al., "Effects of amino acids sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides", Journal of Biological Chemistry 266:22549-22556. (1991). |
V. Agarwal et al., "Recent trends in drug delivery systems: intranasal drug delivery", Indian Journal of Experimental Biology, 37:6-16. (1999). |
Vermehren C:, et al., Drug Metab Dispos Sep. 1997; 25 (9): 1083-8, "Absorption and Metabolism of the Absorption Enhancer Didecanoylphosphatidylcholine in Rabbit Nasal Epithelium in vivo", abstract. |
Wade & Weller, Handbook of Pharmaceutical Excipients, 2nd Edition, American Pharmaceutical Association and the Pharmaceutical Press, pp. 34-37, 122-125, 339-345, 439-440 (1994). |
Windisch, V. et al., "Degradation Pathways of Salmon Calcitonin in Aqueous Solution", J. Pharm. Sci., 86, 359-364. (1997). |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43580E1 (en) * | 2000-02-04 | 2012-08-14 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
US20090317462A1 (en) * | 2007-05-29 | 2009-12-24 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US8513183B2 (en) | 2007-05-29 | 2013-08-20 | Enteris Biopharma, Inc. | Peptide pharmaceutical for oral delivery |
US8592366B2 (en) | 2007-05-29 | 2013-11-26 | Enteris Biopharma, Inc. | Peptide pharmaceutical for oral delivery |
US9399017B2 (en) | 2007-05-29 | 2016-07-26 | Enteris Biopharma, Inc. | Peptide pharmaceutical for oral delivery |
US20100256060A1 (en) * | 2009-04-02 | 2010-10-07 | Unigene Laboratories Inc. | Peptide pharmaceuticals for nasal delivery |
US9457086B2 (en) | 2013-03-05 | 2016-10-04 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
US9526785B2 (en) | 2013-03-05 | 2016-12-27 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
US9744140B2 (en) | 2013-03-05 | 2017-08-29 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
US9833411B2 (en) | 2015-01-12 | 2017-12-05 | Enteris Biopharma, Inc. | Solid oral dosage forms |
Also Published As
Publication number | Publication date |
---|---|
CA2399505A1 (en) | 2001-08-09 |
EP1251867A1 (en) | 2002-10-30 |
US6440392B1 (en) | 2002-08-27 |
WO2001056594A1 (en) | 2001-08-09 |
CA2399505C (en) | 2012-01-03 |
CN1422160A (en) | 2003-06-04 |
EP1251867A4 (en) | 2004-12-08 |
AU3660401A (en) | 2001-08-14 |
USRE43580E1 (en) | 2012-08-14 |
AU783952B2 (en) | 2006-01-05 |
CN1183965C (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE43580E1 (en) | Nasal calcitonin formulations | |
US5902789A (en) | Nasal administration of drugs | |
EP0999841B1 (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
JPH07103043B2 (en) | Calcitonin composition and uses thereof | |
EP0397447B1 (en) | Pharmaceutical compositions | |
US5763398A (en) | Nasal administration of desmopressin | |
US5183802A (en) | Pharmaceutical compositions for intranasal administration of calcitonin | |
EA004761B1 (en) | Stabilized liquid composition of parathyroid hormone, vial containing said composition and process for preparing same | |
US8486891B2 (en) | Nasal calcitonin formulations containing chlorobutanol | |
GB2127689A (en) | Calcitonin inhalation compositions | |
US7893025B2 (en) | Use of growth hormone releasing factor analogs in treating patients suffering from wasting | |
US20100256060A1 (en) | Peptide pharmaceuticals for nasal delivery | |
AU2006299887A1 (en) | PTH formulations and methods of use | |
JPH0354647B2 (en) | ||
JPS6357527A (en) | Method for preventing adsorption of drug | |
US20070213272A1 (en) | Transmucosal Administration Agent Containing Pth | |
JPS63243033A (en) | Nasal administration composition | |
GB2417202A (en) | Pharmaceutical preparation comprising calcitonin | |
IE56602B1 (en) | Galenic compositions comprising calcitonin and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VICTORY PARK MANAGEMENT, LLC, ILLINOIS Free format text: SECURITY AGREEMENT;ASSIGNOR:UNIGENE LABORATORIES, INC.;REEL/FRAME:021630/0352 Effective date: 20080930 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
RR | Request for reexamination filed |
Effective date: 20110715 |
|
AS | Assignment |
Owner name: UNIGENE LABORATORIES INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STERN, WILLIAM;REEL/FRAME:028947/0938 Effective date: 20010208 |
|
RR | Request for reexamination filed |
Effective date: 20121220 |
|
AS | Assignment |
Owner name: UGP THERAPEUTICS, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIGENE LABORATORIES, INC.;REEL/FRAME:030856/0340 Effective date: 20130611 |
|
B1 | Reexamination certificate first reexamination |
Free format text: CLAIMS 1-12, 15, 18 AND 20-23 WERE PREVIOUSLY CANCELLED; CLAIMS 13, 14, 16, 17 AND 24-29 ARE CANCELLED; CLAIM 19 WAS NOT REEXAMINED |
|
B1 | Reexamination certificate first reexamination |
Free format text: THE PATENTABILITY OF CLAIM 19 IS CONFIRMED; CLAIMS 1-18 AND 20-29 WERE PREVIOUSLY CANCELLED |
|
AS | Assignment |
Owner name: ENTERIS BIOPHARMA, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UGP THERAPEUTICS, INC.;REEL/FRAME:039184/0797 Effective date: 20160718 |
|
AS | Assignment |
Owner name: ENTERIS BIOPHARMA, INC., NEW JERSEY Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 039184 FRAME 0797. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE 02/01/2016;ASSIGNOR:UGP THERAPEUTICS, INC.;REEL/FRAME:039682/0212 Effective date: 20160718 |
|
AS | Assignment |
Owner name: UNIGENE LABORATORIES, INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:VICTORY PARK MANAGEMENT, LLC;REEL/FRAME:050000/0762 Effective date: 20130425 |
|
AS | Assignment |
Owner name: CADENCE BANK, N.A., GEORGIA Free format text: SECURITY INTEREST;ASSIGNOR:ENTERIS BIOPHARMA, INC.;REEL/FRAME:050174/0428 Effective date: 20190826 |
|
AS | Assignment |
Owner name: ENTERIS BIOPHARMA, INC., TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CADENCE BANK, A MISSISSIPPI BANK AND SUCCESSOR BY MERGER TO CADENCE BANK, N.A., A NATIONAL BANKING ASSOCIATION, AS AGENT;REEL/FRAME:064149/0741 Effective date: 20230628 |